Researchers identify aluminum hydroxide/TLR9 agonist as potential adjuvant to improve RBD-based COVID-19 vaccine efficacy

By | May 24, 2021
The study findings reveal that RBD-based vaccines adjuvanted with the formulation can induce strong anti-SARS-CoV-2 neutralizing immunity in young and aged mice. The study is currently available on the bioRxiv* preprint server.